TRASTUZUMAB AND TRASTUZUMAB-MCC-DM1 ADMINISTERED INTRAVENOUSLY AND GDC-0941 ADMINISTERED ORALLY TO PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER WHO HAVE PROGRESSED ON PREVIOUS TRASTUZUMAB-BASED THERAPY: